25
2022
-
07
Sinopharm Animal Health R&D Center held a work report meeting in the first half of 2022
On July 22, China Biological Animal Health Research and Development Center held a work report meeting for the first half of 2022, summarizing and reviewing the scientific research work in the first half of the year, deploying scientific research tasks for the second half of the year, and commending advanced collectives and individuals with outstanding performance in the first half of the year.
In the first half of 2022, the research results of the R&D center are gratifying. "Haemophilus suis duplex subunit vaccine" obtained the production number, 5 authorized patents and 6 national, provincial and municipal science and technology projects. The R&D center was rated as the "Advanced Group of Scientific and Technological Innovation" and the "Star of Zhongsheng" Research Star Advanced Group of Sinopharm Group. Zheng Liangyi, director of the Research Office of the Project Research Department, was rated as the "Advanced Individual of Scientific and Technological Innovation" by Sinopharm Group, and together with Mou Linlin, the project leader of the Project Research Department, was recognized as the "Star of Zhongsheng" Advanced Individual of Scientific Research Star.
At the meeting, the heads of each subject and department reported the completion of the work in the first half of 2022 and the work plan for the second half of the year. The participants asked questions and discussed suggestions on the completion of the annual scientific research goals and tasks and the next scientific research development of Sinopharm Animal Protection, and pointed out that In order to solve the shortcomings that restrict scientific research innovation, many new ideas, new goals and new measures have been proposed.
Shi Baolan, deputy general manager and director of the R&D center, summarized the R&D work in the first half of the year. She said that scientific research should focus on advantageous resources, efficiently promote the development of large-scale products, and at the same time establish close linkage with the market, meet the needs of the market, and provide customers with high-quality products and a full range of technical services. In the second half of the year, the focus of work is to focus on the introduction of high-end talents and the planning of large products, adhere to the innovation-driven development strategy, and enhance the market competitiveness of new products.
General Manager Qi Shihua affirmed the work achievements of the R&D center in the first half of the year, and gave guidance on the R&D work from four aspects: personnel structure, innovation ability, scientific research planning and assessment and incentives. He pointed out that it is necessary to strengthen the introduction and training of high-end talents, optimize the personnel structure, attach importance to basic research, improve the original research ability, and make the scientific research ability match the brand of Sinopharm. It is necessary to deeply cultivate the products already on the market, highlight the advantages of the products, and match the R&D investment with the economic benefits generated. He hopes that scientific and technological innovation will make new breakthroughs at the source, occupy a place in the high-end field during the 14th Five-Year Plan period, enhance the industry influence of Sinopharm Animal Health, and support Sinopharm Animal Health and China Biological Animal Health Center's golden brand.
Chief Financial Officer Jing Yumei, Deputy General Manager Sun Wen, heads of various departments and all staff of the R&D Center attended the meeting.
RELATED INFORMATION
CONTACT US
ADDRESS: building A21, biological innovation park, No. 666, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei Province
Copyright © Sinopharm Animal Health Corporation Ltd. All Rights Reserved. SEO Powered by 300.cn